

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS AMENDED BY REGULATION 11 OF THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS 2019/310. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

**Trellus Health plc**  
("Trellus Health", the "Company" or the "Group")

### **Company Update**

**LONDON, U.K. AND NEW YORK, U.S. (21 October 2025)** Trellus Health® plc (AIM: TRLS), a healthcare company delivering Trellus Elevate®, a digital platform that integrates data analytics with personalised, scientifically proven resilience programs and value-based solutions to manage complex chronic conditions, announces an update to cash runway, contract negotiations and fundraising discussions.

#### **Cash Runway**

As announced in the Company's interim results on 8 September 2025, the Company held net cash of 1.6 million as at 30 June 2025, providing a cash runway to early November 2025. Since then, the Board has implemented a number of cost-saving measures, extending the Company's cash runway to early December 2025. In addition, the Company now expects to reduce its average monthly cash burn from approximately 440,000 to around 395,000 going forward.

#### **Contract Negotiations**

As noted in the interim results, the Company had anticipated announcing at least one new collaboration by November. Discussions regarding one collaboration with a leading global CRO to support a mid-stage clinical trial are in late stage contracting. In parallel, negotiations on a separate collaboration with a second leading global CRO are progressing following the Company recently being granted preferred vendor status ("PVS"). Whilst PVS is not revenue generating in itself, being awarded this status by another leading global CRO reinforces the strength and differentiation of Trellus Health's offering in the clinical trials vertical, provides direct access to the CRO's client base, and accelerates procurement and contracting timelines.

The Board continues to anticipate announcing at least one new collaboration before the end of November.

#### **Fundraising**

As previously disclosed, the Board has been exploring options for a potential equity fundraising to support the Company's next phase of growth. Discussions with prospective investors remain ongoing. However, there can be no certainty that any funding transaction will be concluded. No other near-term strategic opportunities have been identified at this time and it is unlikely that any can be identified before early December.

The Board will provide a further update on both the potential fundraising and collaboration discussions in due course.

#### **Enquiries:**

##### **Trellus Health plc**

Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder  
Joy Bessenger, Chief Financial Officer

<https://trellushealth.com/>

**Via Walbrook PR**

##### **Singer Capital Markets**

Jen Boorer / James Todd / Patrick Weaver

Tel: +44 (0)20 7496 3000

##### **Walbrook PR**

Paul McManus / Lianne Applegarth /  
Alice Woodings

Tel: +44 (0)20 7933 8780 or [trellus@walbrookpr.com](mailto:trellus@walbrookpr.com)

Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303/  
+44 (0)7407 804 654

#### **About Trellus Health plc ([www.trellushealth.com](http://www.trellushealth.com))**

Trellus Health® (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous personalised support. Trellus Health's approach empowers patients to better navigate the

solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.

Trellus Health® integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate®, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying the Trellus Elevate® methodology resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions and therapeutic areas, Trellus Health® considers its approach to have potential utility and demand across many conditions.

The Company also offers Trellus TrialSet™, a solution for pharmaceutical partners spanning clinical trials to commercialisation, applying the same validated resilience science and platform to support trial success and long-term patient engagement.

The Company was founded by Icahn School of Medicine at Mount Sinai faculty members Marla C. Dubinsky, MD, and Laurie Keefer, PhD, both world-leading experts in treating both the physical and emotional impacts of IBD, with a combined 50 years of pioneering whole-person healthcare innovation.

Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information, visit: [www.trellushealth.com](http://www.trellushealth.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

UPDFEEESSEIESS